1. need for hospitalization according to updated french guidelines (ministère de la santé_04/04/2020) 2. patient in long-term care facility 3. patient without concern confirmation of covid-19 by laboratory (pcr swab) test or chest ct 4. known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir). 5. any reason making follow up of the patient impossible during the study period.

1. need for hospitalization according to updated french guidelines (ministère de la santé_04/04/2020) 2. patient in long-term care facility 3. patient without concern confirmation of covid-19 by laboratory (pcr swab) test or chest ct 4. known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir). 5. any reason making follow up of the patient impossible during the study period.

need for hospitalization according to updated french guidelines (ministère de la santé_04/04/2020) patient in long-term care facility patient without concern confirmation of covid-19 by laboratory (pcr swab) test or chest ct known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir). any reason making follow up of the patient impossible during the study period.

need for hospitalization according to updated french guidelines (ministère de la santé_04/04/2020) patient in long-term care facility patient without concern confirmation of covid-19 by laboratory (pcr swab) test or chest ct known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir). any reason making follow up of the patient impossible during the study period.

1. need for hospitalization according to updated french guidelines (ministère de la santé_04/04/2020) 2. patient in long-term care facility 3. patient without concern confirmation of covid-19 by laboratory (pcr swab) test or chest ct 4. known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir). 5. any reason making follow up of the patient impossible during the study period.

1. need for hospitalization according to updated french guidelines (ministère de la santé_04/04/2020) 2. patient in long-term care facility 3. patient without concern confirmation of covid-19 by laboratory (pcr swab) test or chest ct 4. known hypersensitivity or contra-indication to the 3 experimental treatments (azithromycin, hydroxychloroquine, lopinavir/ritonavir). 5. any reason making follow up of the patient impossible during the study period.